SBA Member News, 12.10.2015
Gour Medical SA, a veterinary biomedical company, announced today the signing of an agreement with IDEXX Laboratories, Inc. for the development of a therapeutic recombinant monoclonal antibody for use in dogs. Gour plans to continue the development of a therapeutic recombinant dog-specific monoclonal antibody and to launch it in the market. A first product is under development for the treatment and prevention of atopic dermatitis in dogs, a substantial unmet medical need. As a first step, Gour plans to conduct a proof-of-concept study to establish the efficacy of the dog specific recombinant antibody in this indication.
About Gour Medical SA Gour Medical SA, founded in 2014, is a Swiss based veterinary biomedical company, leveraging the advances in human research and applying them to medical solutions for companion animals. Integrated and innovative therapeutic solutions developed by Gour address companion animals' unmet medical needs by treating or preventing significant companion animal health issues. Gour has already signed several cooperation agreements with world renowned companies and laboratories for the development and commercialization of various animal healthcare products